An antibody in the CSF of Parkinson’s disease patients: summary of data and potential role as a diagnostic marker
The CSF of Parkinson’s disease patients was shown to possess an antibody (IgG) which immunocytochemically reacts with dopamine cells in the substantia nigra of the rat. This dopamine neuron antibody (DNAb) was also identified in the CSF of patients with possible nigral degeneration. In contrast, control patients or patients with neurologic disease which is not associated with nigral pathology, did not possess the DNAb in their CSF.
The data is most consistent with a hypothesis which suggests that the DNAb represents a secondary autoinmune response to nigral degeneration. As such, the DNAb may be useful as a diagnostic marker for Parkinson’s disease and other disorders with nigral degeneration. Since nigral degeneration is thought to precede symptom expression by many years, the DNAb should theoretically be present in CSF prior to symptom expression and would thus represent an early, presymptomatic marker of Parkinson’s disease.
KeywordsMultiple Sclerosis Aqueductal Stenosis Immunocytochemical Reactivity Olivopontocerebellar Atrophy Cogwheel Rigidity
Unable to display preview. Download preview PDF.
- Bluestein HG (1984) Antineuronal antibodies in the pathogenesis of neuropsychiatric manifestations of systemic lupus erythematosus. In: Behan P, Spreafico F (eds) Neuroimmunology. Raven Press, New York, pp 157–165Google Scholar
- Carvey PM, Kroin JS, Zhang TJ, O’Dorisio TM, Yaksch TL, McRae A, Dahlstrom A, Kao LC, Goetz CG, Tanner CM, Shannon KM, Klawans HL (1988) Biochemical and immunochemical characterization of ventricular CSF from Parkinson’s disease patients with adrenal medulla transplants. Neurology 38 [Suppl 1]: 144Google Scholar
- Chapman J, Korczyn AD, Hareuveni M, Michaelson DM (1986) Antibodies to cholinergic cell bodies in Alzheimer’s disease. In: Fisher A, Hanin I, Lachman C (eds) Alzheimer’s and Parkinson’s disease. Strategies for research and development. Plenum Press, New York, pp 329–336Google Scholar
- Filit HM, Luine V, Reisberg B, Amador R, McEwen BS, Zabriske JB (1985) Studies of the specificity of autobrain antibodies in Alzheimer’s disease. In: Hutton JT, Kenny AD (eds) Senile dementia. Alan R Liss, New York, pp 307–336Google Scholar
- Franceschi M, Comola M, Nemni R, Pinto P, Iannaccone S, Smirne S, Canal N (1988) Neuron-binding antibodies in Alzheimer’s disease and Down’s syndrome. Neurology 38 [Suppl 1]: 285Google Scholar
- Gaskin F, Kingsly BS, Fu SM (1987) Autoantibodies to neurofibrillary tangles and brain tissue in Alzheimer’s disease. Establishment of Epstein-Barr virus-transformed antibody-producing cell lines. J Exp Med 165: 245–250Google Scholar
- Gonatas NK (1984) Immunohistopathology of experimental allergic encephalomyelitis. In: Behan P, Spreafico F (eds) Neuroimmunology. Raven Press, New York, pp 113–126Google Scholar
- Hornykiewicz O (1979) Compensatory biochemical changes at the striatal dopamine synapse in Parkinson’s disease and limitations of L-dopa therapy. Adv Neurol 24: 275–281Google Scholar
- McFarlin DE (1984) Immunologic abnormalities associated with neurologic diseases. In: Behan P, Spreafico F (eds) Neuroimmunology. Raven Press, New York, pp 237–245Google Scholar
- McRae-Degueurce A, Booj S, Haglid K, Rosengran L, Karlsson JE, Karlsson I, Wallin A, Svennerholm L, Gottfries C-G, Dahlstrom A (1987) Antibodies in cerebrospinal fluid of some Alzheimer’s disease patients recognize cholinergic neurons in the rat central nervous system. Proc Natl Acad Sci 84: 9214–9218PubMedCrossRefGoogle Scholar
- McRae A, Dahlstrom A, Klawans FIL, Goetz CG, Tanner CM, Penn RD, Carvey PM (1989) Adrenal medulla transplantation in Parkinson’s disease reduces the presence of a CSF antibody to the rat substantia nigra. Neurology 39 [Suppl 11: 364Google Scholar
- Solimena M, Folli F, Pozza G, De Camilli P (1989) Autoantibodies directed against GABAergic synapses in stiff-man syndrome. Neurology 39 [Suppl 1]: 384Google Scholar
- 40.P. M. Carvey et al.: Dopamine-neuron antibody in Parkinson’s diseaseGoogle Scholar
- Tourtellotte WW, Potvin AR, Potvin HH, Ma BI, Baumhefner RW, Syndulko K (1980) Multiple sclerosis de novo CNS IgG synthesis: measurement, antibody profile, significance eradication, and problems. In: Bauer HJ, Poser S, Ritter G (eds) Progress in multiple sclerosis. Springer, Berlin Heidelberg New York, pp 106–110CrossRefGoogle Scholar